drugset / Trial / NCT07033026
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Timeline
- Start
- 2025-06-25
- Primary completion
- 2027-04
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NGM120 | Monoclonal antibody | — | Subcutaneous |